Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides pteronyssinus + dermatophagoides farinae allergen extract
- Development stage
- Phase 2
- Lead developer
- Inmunotek
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual, Subcutaneous
01
Overview
Dermatophagoides pteronyssinus + Dermatophagoides farinae allergen extract is a house dust mite (HDM) allergen immunotherapy developed by Inmunotek, S.L. It is a biologic product composed of standardized allergen extracts derived from the two most prevalent house dust mite species worldwide: *Dermatophagoides pteronyssinus* (Der p) and *Dermatophagoides farinae* (Der f). The therapy is designed to treat allergic rhinitis, allergic rhinoconjunctivitis, and general house dust mite hypersensitivity by inducing immunological tolerance and modulating IgE-mediated allergic responses. It is administered via sublingual (e.g., Oraltek spray) or subcutaneous (e.g., Alxoid polymerized allergoid) routes. The product has been evaluated in Phase 2 dose-finding clinical trials in Spain to characterize its efficacy, safety, and optimal dosing using nasal provocation threshold changes and skin prick tests.
- Brand names
- OraltekAlxoid
- Other names
- Dermatophagoides pteronyssinus + Dermatophagoides farinae allergen extractDermatophagoides pteronyssinus and Dermatophagoides farinae extractHDM allergen extractHouse dust mite allergen extractMite allergen immunotherapy
02
Targets
HDM-BCR (Allergen-specific B-cell receptor recognizing house dust mite allergen)γδ TCR (T-cell receptor)PDX1 (Pancreas/duodenum homeobox protein 1)PAR (Protease-activated receptors)
Beyond the preview
Go deeper on dermatophagoides pteronyssinus + dermatophagoides farinae allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides pteronyssinus + dermatophagoides farinae allergen extract.